Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like...

Descripción completa

Detalles Bibliográficos
Autores: Ficarra, Guido, Prat Aparicio, Aleix, Conte, Pierfranco, Guarneri, Valentina, Griguolo, Gaia, Dieci, Maria Vittoria, Paré, Laia, Miglietta, Federica, Generali, Daniele, Frassoldati, Antonio, Cavanna, Luigi, Bisagni, Giancarlo, Piacentini, Federico, Tagliafico, Enrico, Cagossi, Katia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/226145
Acceso en línea:https://hdl.handle.net/2445/226145
Access Level:acceso abierto
Palabra clave:Càncer de mama
Receptors d'hormones
Antígens tumorals
Breast cancer
Hormone receptors
Tumor antigens
Descripción
Sumario:Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocytelevels than luminal tumors. Moreover, significant differences in immune infiltrate composition,assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatoryantitumor immune infiltrate composition than luminal ones.

Similares en LA Referencia